News

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...
BioSpace23h
Ventyx’s Parkinson’s Pill Shows ‘Promising’ Results in Mid-Stage Study, Paving Path to Other Neuro Diseases
Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...
Fierce Biotech23h
Ventyx posts phase 2 Parkinson's data ahead of potential talks with Sanofi
Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...
InvestorsHub on MSN23h
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results
Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...